PharmiWeb.com - Global Pharma News & Resources
01-Mar-2023

Horizon Therapeutics plc Reports Fourth-Quarter and Full-Year 2022 Financial Results

Fourth-Quarter 2022 Results:
-- Net Sales of $942.0 Million --
-- GAAP Net Income of $120.4 Million; Adjusted EBITDA of $357.5 Million; Includes $37.3 Million of Acquired IPR&D and Milestones Expenses --
-- TEPEZZA® (teprotumumab-trbw) Net Sales of $493.5 Million --
-- KRYSTEXXA® (pegloticase injection) Net Sales of $216.1 Million --
-- UPLIZNA® (inebilizumab-cdon) Net Sales of $41.8 Million --

Full-Year 2022 Results:
-- Record Net Sales of $3.63 Billion; Year-Over-Year Increase of 12% --
-- GAAP Net Income of $521.5 Million; Record Adjusted EBITDA of $1.37 Billion; Includes $56.3 Million of Acquired IPR&D and Milestones Expenses --
-- Record TEPEZZA Net Sales of $1.97 Billion; Year-Over-Year Increase of 18% --
-- Record KRYSTEXXA Net Sales of $716.2 Million; Year-Over-Year Increase of 27% --
-- Record UPLIZNA Net Sales of $154.6 Million; Year-Over-Year Increase of 154% --
-- Record Operating Cash Flow of $1.26 Billion --
-- Cash Position of $2.35 Billion as of Dec. 31, 2022 --

Fourth-Quarter and Recent Company Highlights:
-- Entered into Agreement to Be Acquired by Amgen Inc.; Transaction Expected to Close in 1H23 --
-- Announced Positive Topline Data from the Second Population in Dazodalibep Sjögren’s Syndrome Phase 2 Trial; First and Only Phase 2 Sjögren’s Syndrome Trial to Meet the Primary Endpoint in Both Patient Populations; Phase 3 Clinical Program Expected to Initiate in 2023 --
-- Completed Enrollment in TEPEZZA Phase 3 Trial in Japan (OPTIC-J) in Active Thyroid Eye Disease (TED); Topline Results Expected in 3Q23 --
-- Expect Topline Results from U.S. TEPEZZA Chronic/Low Clinical Activity Score (CAS) TED Trial in 2Q23 --
-- Expect to Initiate TEPEZZA Phase 3 Trial in Japan in Chronic/Low CAS TED in 2023 --
-- Received Approval for UPLIZNA in Brazil for the Treatment of Adult Patients with Neuromyelitis Optica Spectrum Disorder --
-- Initiated Daxdilimab Discoid Lupus Erythematosus Phase 2 Trial, HZN-457 Gout Phase 1 Trial and ADX-914 Atopic Dermatitis Phase 2 Trial in Collaboration with Q32 Bio --

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced fourth-quarter and record full-year 2022 financial results.


“2022 marked another impressive year for Horizon, with double-digit net sales growth across our commercial portfolio and significant progress executing on our strategy to maximize the value of our growth medicines, expand our global presence and advance our pipeline, including generating positive topline results from our Phase 2 trial in Sjögren’s syndrome across both patient populations,” said Tim Walbert, chairman, president and chief executive officer, Horizon. “I am extremely proud of what we have accomplished – not only in the last year, but over the last decade. We have built a leading, innovation-driven, profitable biotechnology company that is well-positioned going forward as we prepare to become part of Amgen.”

Financial Highlights

(in millions except for per share amounts and percentages) Q4 22 Q4 21 %
Change
FY 22 FY 21 %
Change
 
Net sales

$

942.0

$

1,014.5

(7

)

$

3,629.0

$

3,226.4

12

 

Net income

 

120.4

 

173.2

(30

)

 

521.5

 

534.5

(2

)

Non-GAAP net income

 

281.5

 

334.0

(16

)

 

1,144.3

 

1,089.7

5

 

Adjusted EBITDA(1)

 

357.5

 

416.0

(14

)

 

1,370.6

 

1,284.3

7

 

 
Earnings per share - diluted

 

0.52

 

0.73

(29

)

 

2.22

 

2.27

(2

)

Non-GAAP earnings per share - diluted

 

1.21

 

1.41

(14

)

 

4.86

 

4.62

5

 

 
(1)

Fourth-quarter 2022 and 2021 adjusted EBITDA includes $37.3 million and $39.7 million, respectively, in acquired in-process research and development (IPR&D) and milestones expenses. Full-year 2022 and 2021 adjusted EBITDA includes $56.3 million and $86.7 million, respectively, in acquired IPR&D and milestones expenses.

Fourth-Quarter and Full-Year 2022 Net Sales Results

Beginning in the fourth quarter of 2022, the Company started operating and reporting as a single reporting segment as a result of the wind-down of the Company’s former inflammation business.

(in millions except for percentages) Q4 22 Q4 21 %
Change
FY 22 FY 21 %
Change
 
 
TEPEZZA®(1)

$

493.5

$

589.6

(16

)

$

1,965.7

$

1,661.3

18

 

KRYSTEXXA®

 

216.1

 

170.3

27

 

 

716.2

 

565.5

27

 

RAVICTI®

 

87.5

 

74.4

18

 

 

325.6

 

291.9

12

 

PROCYSBI®

 

54.9

 

47.4

16

 

 

210.0

 

189.9

11

 

UPLIZNA®(2)

 

41.8

 

25.8

62

 

 

154.6

 

60.8

154

 

ACTIMMUNE®

 

30.1

 

30.6

(1

)

 

126.1

 

117.2

8

 

PENNSAID 2%®(3)

 

7.2

 

48.9

(85

)

 

73.8

 

191.6

(61

)

RAYOS®

 

6.7

 

13.3

(50

)

 

41.9

 

56.9

(26

)

BUPHENYL®

 

2.1

 

2.1

(0

)

 

7.3

 

7.9

(7

)

DUEXIS®(4)

 

1.7

 

11.5

(85

)

 

4.9

 

74.0

(93

)

QUINSAIRTM

 

0.2

 

0.3

(22

)

 

1.1

 

1.0

5

 

VIMOVO®

 

0.2

 

0.3

(40

)

 

1.8

 

8.4

(78

)

Total Net Sales

$

942.0

$

1,014.5

(7

)

$

3,629.0

$

3,226.4

12

 

(1)

TEPEZZA net sales in the fourth quarter of 2021 accounted for a larger share of full-year 2021 net sales due to a supply disruption caused by the U.S. government-mandated COVID-19 vaccine orders.

(2)

Fourth-quarter and full-year 2022 UPLIZNA net sales included $1.3 million and $18.3 million, respectively, in international net sales, related primarily to revenue and milestone payments from the Company’s international partners.

(3)

On May 6, 2022, Apotex Inc. initiated an at-risk launch of generic PENNSAID 2% in the United States.

(4)

On Aug. 4, 2021, Alkem Laboratories, Inc. initiated an at-risk launch of generic DUEXIS in the United States.

Conference Call

In light of the announced agreement to be acquired by Amgen Inc. and applicable securities laws, Horizon will not be hosting a conference call to discuss its financial results. The earnings press release and SEC Form 10-K are publicly available in the Investor Relations section of the Company’s website at https://ir.horizontherapeutics.com.

About Horizon

Horizon is a global biotechnology company focused on the discovery, development and commercialization of medicines that address critical needs for people impacted by rare, autoimmune and severe inflammatory diseases. Our pipeline is purposeful: we apply scientific expertise and courage to bring clinically meaningful therapies to patients. We believe science and compassion must work together to transform lives. For more information on how we go to incredible lengths to impact lives, visit www.horizontherapeutics.com and follow us on Twitter, LinkedIn, Instagram and Facebook.

Note Regarding Use of Non-GAAP Financial Measures

Horizon provides certain non-GAAP financial measures, including EBITDA, or earnings before interest, taxes, depreciation and amortization, adjusted EBITDA, non-GAAP net income, non-GAAP diluted earnings per share, non-GAAP gross profit and gross profit ratio, non-GAAP operating expenses, non-GAAP operating income, non-GAAP tax benefit (expense) and tax rate, non-GAAP operating cash flow and certain other non-GAAP income statement line items, each of which include adjustments to GAAP figures. These non-GAAP measures are intended to provide additional information on Horizon’s performance, operations, expenses, profitability and cash flows. Adjustments to Horizon’s GAAP figures exclude, as applicable, acquisition and/or divestiture-related costs, costs associated with our pending transaction with Amgen Inc. as well as the process leading to the transaction, manufacturing facility start-up costs, restructuring and realignment costs, as well as non-cash items such as share-based compensation, inventory step-up expense, depreciation and amortization, non-cash interest expense, goodwill and long-lived assets impairment charges, gain (loss) on equity security investments and sales of assets and other non-cash adjustments. Certain other special items or substantive events may also be included in the non-GAAP adjustments periodically when their magnitude is significant within the periods incurred. Horizon maintains an established non-GAAP cost policy that guides the determination of what costs will be excluded in non-GAAP measures. Horizon believes that these non-GAAP financial measures, when considered together with the GAAP figures, can enhance an overall understanding of Horizon’s financial and operating performance. The non-GAAP financial measures are included with the intent of providing investors with a more complete understanding of the Company’s historical and expected financial results and trends and to facilitate comparisons between periods and with respect to projected information. In addition, these non-GAAP financial measures are among the indicators Horizon’s management uses for planning and forecasting purposes and measuring the Company's performance. These non-GAAP financial measures should be considered in addition to, and not as a substitute for, or superior to, financial measures calculated in accordance with GAAP. The non-GAAP financial measures used by the Company may be calculated differently from, and therefore may not be comparable to, non-GAAP financial measures used by other companies.

Forward-Looking Statements

This press release contains forward-looking statements, including, but not limited to, statements related to the pending transaction with Amgen Inc., development, manufacturing and commercialization plans; expected timing of clinical trials and, availability of clinical data; expected future milestones, pipeline expansions and regulatory approvals; potential market opportunities for, and benefits of, Horizon’s medicines and medicine candidates and business and other statements that are not historical facts. These forward-looking statements are based on Horizon’s current expectations and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, whether the pending transaction with Amgen Inc. will be completed in a timely manner or at all; the parties’ ability to satisfy (or willingness to waive) the conditions to the consummation of the pending transaction with Amgen Inc., including with respect to required regulatory approvals; the effect of the pending transaction with Amgen Inc. on Horizon’s business relationships, operating results and business generally; risks that Horizon’s actual future financial and operating results may differ from its expectations or goals; Horizon’s ability to grow net sales from existing medicines; impacts of the COVID-19 pandemic and actions taken to slow its spread, including impacts on supplies and net sales of Horizon’s medicines and potential delays in clinical trials; impacts of the on-going war between Russia and Ukraine; changes in inflation, interest rates and general economic conditions; the availability of coverage and adequate reimbursement and pricing from government and third-party payers; Horizon’s ability to successfully implement its business strategies, including the risks that its medicine growth and global expansion initiatives and strategies may not be successful and that new challenges to growth may arise in the future; risks inherent in developing novel medicine candidates and existing medicines for new indications; risks associated with regulatory approvals; risks in the ability to recruit, train and retain qualified personnel; competition, including generic competition; the ability to protect intellectual property and defend patents; regulatory obligations and oversight, including any changes in the legal and regulatory environment in which Horizon operates and those risks detailed from time-to-time under the caption "Risk Factors" and elsewhere in Horizon’s filings and reports with the SEC. Horizon undertakes no duty or obligation to update any forward-looking statements contained in this press release as a result of new information.

Horizon Therapeutics plc
Condensed Consolidated Statements of Operations
(in thousands, except share and per share data)
 
Three Months Ended December 31, Twelve Months Ended December 31,

 

2022

 

 

2021

 

 

2022

 

 

2021

 

(Unaudited)
Net sales

$

942,029

 

$

1,014,464

 

$

3,629,044

 

$

3,226,410

 

Cost of goods sold

 

240,787

 

 

241,509

 

 

920,197

 

 

794,512

 

Gross profit

 

701,242

 

 

772,955

 

 

2,708,847

 

 

2,431,898

 

 
OPERATING EXPENSES:
Research and development (1)

 

117,526

 

 

101,242

 

 

437,962

 

 

345,318

 

Acquired in-process research and development and milestones(1)

 

37,250

 

 

39,672

 

 

56,250

 

 

86,672

 

Selling, general and administrative

 

372,534

 

 

398,954

 

 

1,541,052

 

 

1,446,410

 

Impairment of goodwill

 

-

 

 

-

 

 

56,171

 

 

-

 

Impairment of long-lived asset

 

-

 

 

-

 

 

-

 

 

12,371

 

Gain on sale of asset

 

-

 

 

-

 

 

-

 

 

(2,000

)

Total operating expenses

 

527,310

 

 

539,868

 

 

2,091,435

 

 

1,888,771

 

Operating income

 

173,932

 

 

233,087

 

 

617,412

 

 

543,127

 

 
OTHER EXPENSE, NET:
Interest expense, net

 

(18,562

)

 

(22,045

)

 

(83,707

)

 

(81,063

)

Foreign exchange (loss) gain

 

(882

)

 

335

 

 

(1,202

)

 

(1,028

)

Other (expense) income, net

 

(159

)

 

(322

)

 

(5,567

)

 

1,791

 

Total other expense, net

 

(19,603

)

 

(22,032

)

 

(90,476

)

 

(80,300

)

 
Income before expense (benefit) for income taxes

 

154,329

 

 

211,055

 

 

526,936

 

 

462,827

 

Expense (benefit) for income taxes

 

33,921

 

 

37,873

 

 

5,454

 

 

(71,664

)

Net income

$

120,408

 

$

173,182

 

$

521,482

 

$

534,491

 

 
Net income per ordinary share - basic

$

0.53

 

$

0.76

 

$

2.28

 

$

2.37

 

 
Weighted average ordinary shares outstanding - basic

 

226,997,506

 

 

227,028,298

 

 

229,108,881

 

 

225,551,410

 

 
Net income per ordinary share - diluted

$

0.52

 

$

0.73

 

$

2.22

 

$

2.27

 

 
Weighted average ordinary shares outstanding - diluted

 

233,014,974

 

 

236,806,923

 

 

235,239,651

 

 

235,680,483

 

 
 

(1)

Beginning with the third quarter of 2022, the Company is separately presenting upfront, milestone, and similar payments pursuant to collaborations, licenses of third-party technologies, and asset acquisitions as “Acquired in-process research and development and milestones” expenses in the condensed consolidated statements of operations. Amounts recorded in this line item for the three and twelve months ended December 31, 2022, would have historically been recorded to research and development (“R&D”) expenses. The Company believes the new classification assists users of the financial statements in better understanding the payments incurred to acquire in-process research and development (“IPR&D”). Prior period condensed consolidated statements of operations have been reclassified to conform with the new classification.
 
Horizon Therapeutics plc
Condensed Consolidated Balance Sheets
(in thousands, except share data)
 
 
As of
December 31,
2022
December 31,
2021
ASSETS
CURRENT ASSETS:
Cash and cash equivalents

$

2,352,833

 

$

1,580,317

 

Restricted cash

 

4,755

 

 

3,839

 

Accounts receivable, net

 

676,347

 

 

632,775

 

Inventories, net

 

169,559

 

 

225,730

 

Prepaid expenses and other current assets

 

449,349

 

 

357,106

 

Total current assets

 

3,652,843

 

 

2,799,767

 

Property, plant and equipment, net

 

340,509

 

 

292,298

 

Developed technology and other intangible assets, net

 

2,664,777

 

 

2,960,118

 

In-process research and development

 

810,000

 

 

880,000

 

Goodwill

 

1,010,538

 

 

1,066,709

 

Deferred tax assets, net

 

431,814

 

 

538,098

 

Other long-term assets

 

204,135

 

 

140,738

 

Total assets

$

9,114,616

 

$

8,677,728

 

 
LIABILITIES AND SHAREHOLDERS' EQUITY
CURRENT LIABILITIES:
Accounts payable

$

155,800

 

$

30,125

 

Accrued expenses and other current liabilities

 

457,557

 

 

523,015

 

Accrued trade discounts and rebates

 

319,780

 

 

317,431

 

Long-term debt—current portion

 

16,000

 

 

16,000

 

Total current liabilities

 

949,137

 

 

886,571

 

 
LONG-TERM LIABILITIES:
Long-term debt, net

 

2,546,837

 

 

2,555,233

 

Deferred tax liabilities, net

 

342,017

 

 

390,455

 

Other long-term liabilities

 

204,451

 

 

173,076

 

Total long-term liabilities

 

3,093,305

 

 

3,118,764

 

 
COMMITMENTS AND CONTINGENCIES
SHAREHOLDERS' EQUITY:
Ordinary shares, $0.0001 nominal value; 600,000,000 shares
authorized at December 31, 2022 and December 31, 2021;
227,625,913 and 227,760,936 shares issued at December 31, 2022
and December 31, 2021, respectively; and 227,241,547 and 227,376,570 shares
outstanding at December 31, 2022 and December 31, 2021, respectively

 

23

 

 

23

 

Treasury stock, 384,366 ordinary shares at December 31, 2022 and December 31, 2021

 

(4,585

)

 

(4,585

)

Additional paid-in capital

 

4,474,199

 

 

4,373,337

 

Accumulated other comprehensive income (loss)

 

12,528

 

 

(14,987

)

Retained earnings

 

590,009

 

 

318,605

 

Total shareholders' equity

 

5,072,174

 

 

4,672,393

 

Total liabilities and shareholders' equity

$

9,114,616

 

$

8,677,728

 

Horizon Therapeutics plc
Condensed Consolidated Statements of Cash Flows
(in thousands)
 
 
Three Months Ended December 31, Twelve Months Ended December 31,

 

2022

 

 

2021

 

 

2022

 

 

2021

 

(Unaudited)
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income

$

120,408

 

$

173,182

 

$

521,482

 

$

534,491

 

Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization expense

 

98,774

 

 

96,535

 

 

390,393

 

 

353,751

 

Equity-settled share-based compensation

 

44,585

 

 

48,692

 

 

182,100

 

 

219,086

 

Acquired IPR&D and milestones

 

37,250

 

 

30,072

 

 

52,250

 

 

70,072

 

Impairment of goodwill

 

-

 

 

-

 

 

56,171

 

 

-

 

Impairment of long-lived asset

 

-

 

 

-

 

 

-

 

 

12,371

 

Amortization of debt discount and deferred financing costs

 

1,776

 

 

1,449

 

 

7,912

 

 

5,189

 

Gain on sale of asset

 

-

 

 

-

 

 

-

 

 

(2,000

)

Deferred income taxes

 

41,160

 

 

46,918

 

 

49,814

 

 

(101,016

)

Foreign exchange and other adjustments

 

2,004

 

 

61

 

 

9,700

 

 

5,067

 

Changes in operating assets and liabilities:
Accounts receivable

 

(29,776

)

 

142,572

 

 

(43,457

)

 

34,796

 

Inventories

 

20,713

 

 

11,761

 

 

56,122

 

 

1,267

 

Prepaid expenses and other current assets

 

(4,588

)

 

(27,403

)

 

(79,245

)

 

(88,193

)

Accounts payable

 

123,087

 

 

(19,837

)

 

122,232

 

 

(12,197

)

Accrued trade discounts and rebates

 

(35,890

)

 

13,909

 

 

2,399

 

 

(36,929

)

Accrued expenses and other current liabilities

 

5,887

 

 

16,242

 

 

(59,101

)

 

50,622

 

Other non-current assets and liabilities

 

1,001

 

 

4,404

 

 

(10,930

)

 

(11,106

)

Net cash provided by operating activities

 

426,391

 

 

538,557

 

 

1,257,842

 

 

1,035,271

 

CASH FLOWS FROM INVESTING ACTIVITIES:
Payments for acquisitions, net of cash acquired

 

-

 

 

-

 

 

(3,122

)

 

(2,843,275

)

Purchases of property, plant and equipment

 

(24,858

)

 

(16,901

)

 

(64,026

)

 

(76,596

)

Payments for long-term investments

 

(2,180

)

 

(14,871

)

 

(9,236

)

 

(28,256

)

Receipts from long-term investments

 

217

 

 

-

 

 

4,633

 

 

3,588

 

Proceeds from sale of asset

 

-

 

 

-

 

 

-

 

 

2,000

 

Payments related to license and collaboration agreements

 

(22,250

)

 

(5,072

)

 

(62,250

)

 

(51,572

)

Net cash used in investing activities

 

(49,071

)

 

(36,844

)

 

(134,001

)

 

(2,994,111

)

CASH FLOWS FROM FINANCING ACTIVITIES:
Net proceeds from term loans

 

-

 

 

-

 

 

-

 

 

1,574,993

 

Repayment of term loans

 

(4,000

)

 

(4,000

)

 

(16,000

)

 

(12,000

)

Proceeds from the issuance of ordinary shares in conjunction with ESPP program

 

11,167

 

 

11,046

 

 

25,051

 

 

22,528

 

Proceeds from the issuance of ordinary shares in connection with stock option exercises

 

7,036

 

 

10,553

 

 

30,316

 

 

50,566

 

Payment of employee withholding taxes relating to share-based awards

 

(13,300

)

 

(7,887

)

 

(137,247

)

 

(165,964

)

Repurchase of ordinary shares

 

(161,869

)

 

-

 

 

(250,078

)

 

-

 

Net cash (used in) provided by financing activities

 

(160,966

)

 

9,712

 

 

(347,958

)

 

1,470,123

 

 
Effect of foreign exchange rate changes on cash, cash equivalents and restricted cash

 

5,964

 

 

345

 

 

(2,451

)

 

(10,606

)

 
Net increase (decrease) in cash, cash equivalents and restricted cash

 

222,318

 

 

511,770

 

 

773,432

 

 

(499,323

)

Cash, cash equivalents and restricted cash, beginning of the period(1)

 

2,135,270

 

 

1,072,386

 

 

1,584,156

 

 

2,083,479

 

Cash, cash equivalents and restricted cash, end of the period(1)

$

2,357,588

 

$

1,584,156

 

$

2,357,588

 

$

1,584,156

 

 
 
(1) Amounts include restricted cash balance in accordance with ASU No. 2016-18. Cash and cash equivalents excluding restricted cash are shown on the balance sheet.
Horizon Therapeutics plc
GAAP to Non-GAAP Reconciliations
Net Income and Earnings Per Share (Unaudited)
(in thousands, except share and per share data)
 
 
Three Months Ended December 31, Twelve Months Ended December 31,

 

2022

 

 

2021

 

 

2022

 

 

2021

 

 
GAAP net income

$

120,408

 

$

173,182

 

$

521,482

 

$

534,491

 

Non-GAAP adjustments:
Acquisition/divestiture-related costs

 

(3,676

)

 

7,763

 

 

(239

)

 

95,929

 

Transaction-related costs

 

11,086

 

 

-

 

 

11,086

 

 

-

 

(Gain) loss on equity security investments

 

(143

)

 

(1,257

)

 

6,188

 

 

(1,257

)

Restructuring and realignment costs

 

7,456

 

 

18,606

 

 

16,977

 

 

26,309

 

Manufacturing facility start-up costs

 

1,139

 

 

1,910

 

 

5,552

 

 

3,622

 

Amortization and step-up:
Intangible amortization expense

 

92,916

 

 

91,017

 

 

366,462

 

 

336,277

 

Inventory step-up expense

 

25,367

 

 

10,658

 

 

91,709

 

 

27,572

 

Amortization of debt discount and deferred financing costs

 

1,776

 

 

1,449

 

 

7,912

 

 

5,189

 

Impairment of long-lived asset

 

-

 

 

-

 

 

-

 

 

12,371

 

Impairment of goodwill

 

-

 

 

-

 

 

56,171

 

 

-

 

Gain on sale of asset

 

-

 

 

-

 

 

-

 

 

(2,000

)

Share-based compensation

 

44,585

 

 

48,692

 

 

182,100

 

 

219,086

 

Depreciation

 

5,858

 

 

5,519

 

 

23,931

 

 

17,475

 

Litigation settlement

 

-

 

 

-

 

 

-

 

 

5,000

 

Total of pre-tax non-GAAP adjustments

 

186,364

 

 

184,357

 

 

767,849

 

 

745,573

 

Income tax effect of pre-tax non-GAAP adjustments

 

(26,619

)

 

(27,889

)

 

(148,373

)

 

(169,554

)

Other non-GAAP income tax adjustments

 

1,308

 

 

4,326

 

 

3,387

 

 

(20,800

)

Total of non-GAAP adjustments

 

161,053

 

 

160,794

 

 

622,863

 

 

555,219

 

Non-GAAP net income

$

281,461

 

$

333,976

 

$

1,144,345

 

$

1,089,710

 

 
 
Non-GAAP Earnings Per Share:
 
Weighted average ordinary shares - Basic

 

226,997,506

 

 

227,028,298

 

 

229,108,881

 

 

225,551,410

 

 
Non-GAAP Earnings Per Share - Basic:
GAAP earnings per share - Basic

$

0.53

 

$

0.76

 

$

2.28

 

$

2.37

 

Non-GAAP adjustments

 

0.71

 

 

0.71

 

 

2.71

 

 

2.46

 

Non-GAAP earnings per share - Basic

$

1.24

 

$

1.47

 

$

4.99

 

$

4.83

 

 
Weighted average ordinary shares - Diluted
Weighted average ordinary shares - Basic

 

226,997,506

 

 

227,028,298

 

 

229,108,881

 

 

225,551,410

 

Ordinary share equivalents

 

6,017,468

 

 

9,778,625

 

 

6,130,771

 

 

10,129,073

 

Weighted average ordinary shares - Diluted

 

233,014,974

 

 

236,806,923

 

 

235,239,652

 

 

235,680,483

 

 
Non-GAAP Earnings Per Share - Diluted
GAAP earnings per share - Diluted

$

0.52

 

$

0.73

 

$

2.22

 

$

2.27

 

Non-GAAP adjustments

 

0.69

 

 

0.68

 

 

2.64

 

 

2.35

 

Non-GAAP earnings per share - Diluted

$

1.21

 

$

1.41

 

$

4.86

 

$

4.62

 

 
Horizon Therapeutics plc
GAAP to Non-GAAP Reconciliations
EBITDA and Adjusted EBITDA (Unaudited)
(in thousands)
 
 
Three Months Ended December 31, Twelve Months Ended December 31,

 

2022

 

 

2021

 

 

2022

 

 

2021

 

 
 
 
GAAP net income

$

120,408

 

$

173,182

 

$

521,482

 

$

534,491

 

Depreciation

 

5,858

 

 

5,519

 

 

23,931

 

 

17,475

 

Amortization and step-up:
Intangible amortization expense

 

92,916

 

 

91,017

 

 

366,462

 

 

336,277

 

Inventory step-up expense

 

25,367

 

 

10,658

 

 

91,709

 

 

27,572

 

Interest expense, net (including amortization of
debt discount and deferred financing costs)

 

18,562

 

 

22,045

 

 

83,707

 

 

81,063

 

Expense (benefit) for income taxes

 

33,921

 

 

37,873

 

 

5,454

 

 

(71,664

)

EBITDA

$

297,032

 

$

340,294

 

$

1,092,745

 

$

925,214

 

Other non-GAAP adjustments:
Share-based compensation

 

44,585

 

 

48,692

 

 

182,100

 

 

219,086

 

(Gain) loss on equity security investments

 

(143

)

 

(1,257

)

 

6,188

 

 

(1,257

)

Acquisition/divestiture-related costs

 

(3,676

)

 

7,763

 

 

(239

)

 

95,929

 

Transaction-related costs

 

11,086

 

 

-

 

 

11,086

 

 

-

 

Manufacturing facility start-up costs

 

1,139

 

 

1,910

 

 

5,552

 

 

3,622

 

Restructuring and realignment costs

 

7,456

 

 

18,606

 

 

16,977

 

 

26,309

 

Impairment of goodwill

 

-

 

 

-

 

 

56,171

 

 

-

 

Impairment of long-lived asset

 

-

 

 

-

 

 

-

 

 

12,371

 

Gain on sale of asset

 

-

 

 

-

 

 

-

 

 

(2,000

)

Litigation settlement

 

-

 

 

-

 

 

-

 

 

5,000

 

Total of other non-GAAP adjustments

 

60,447

 

 

75,714

 

 

277,835

 

 

359,060

 

Adjusted EBITDA

$

357,479

 

$

416,008

 

$

1,370,580

 

$

1,284,274

 

 

Contacts

Investors:
Tina Ventura
Senior Vice President,
Chief Investor Relations Officer
investor-relations@horizontherapeutics.com

Erin Linnihan
Executive Director,
Investor Relations
investor-relations@horizontherapeutics.com

U.S. Media:
Geoff Curtis
Executive Vice President,
Corporate Affairs & Chief Communications Officer
media@horizontherapeutics.com

Ireland Media:
Ray Gordon
Gordon MRM
ray@gordonmrm.ie


Read full story here

Editor Details

  • Company:
    • Businesswire
Last Updated: 01-Mar-2023